Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM.

Radiother Oncol. 2019 Sep 17. pii: S0167-8140(19)33066-X. doi: 10.1016/j.radonc.2019.08.020. [Epub ahead of print]

PMID:
31540746
2.

Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality.

Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, Amling CL, Aronson WJ, Kane CJ, Terris MK, Zumsteg ZS, Butler S, Osborne JR, Morgan TM, Mehra R, Salami SS, Kishan AU, Wang C, Schaeffer EM, Roach M 3rd, Pisansky TM, Shipley WU, Freedland SJ, Sandler HM, Halabi S, Feng FY, Dignam JJ, Nguyen PL, Schipper MJ, Spratt DE.

JAMA Oncol. 2019 Jul 1;5(7):975-983. doi: 10.1001/jamaoncol.2019.0826.

3.

The current state of randomized clinical trial evidence for prostate brachytherapy.

Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE.

Urol Oncol. 2019 Sep;37(9):599-610. doi: 10.1016/j.urolonc.2019.04.009. Epub 2019 May 3. Review.

PMID:
31060795
4.

Adjuvant and Salvage Radiation Therapy After Prostatectomy: ASTRO/AUA Guideline Amendment, Executive Summary 2018.

Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S.

Pract Radiat Oncol. 2019 Jul - Aug;9(4):208-213. doi: 10.1016/j.prro.2019.04.008. Epub 2019 Apr 30.

PMID:
31051281
5.

Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.

Pisansky TM, Thompson IM, Valicenti RK, D'Amico AV, Selvarajah S.

J Urol. 2019 Sep;202(3):533-538. doi: 10.1097/JU.0000000000000295. Epub 2019 Aug 8.

PMID:
31042111
6.

Tolerance doses for late adverse events after hypofractionated radiotherapy for prostate cancer on trial NRG Oncology/RTOG 0415.

Thor M, Deasy JO, Paulus R, Robert Lee W, Amin MB, Bruner DW, Low DA, Shah AB, Malone SC, Michalski JM, Dayes IS, Seaward SA, Gore EM, Albert M, Pisansky TM, Faria SL, Chen Y, Koontz BF, Swanson GP, Pugh SL, Sandler HM.

Radiother Oncol. 2019 Jun;135:19-24. doi: 10.1016/j.radonc.2019.02.014. Epub 2019 Mar 5.

PMID:
31015166
7.

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases.

Gao RW, Olivier KR, Park SS, Davis BJ, Pisansky TM, Choo R, Kwon ED, Karnes RJ, Harmsen WS, Stish BJ.

Adv Radiat Oncol. 2019 Feb 19;4(2):314-322. doi: 10.1016/j.adro.2019.02.002. eCollection 2019 Apr-Jun.

8.

Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.

Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M 3rd, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM.

Int J Radiat Oncol Biol Phys. 2019 Aug 1;104(5):1057-1065. doi: 10.1016/j.ijrobp.2019.03.049. Epub 2019 Apr 6.

PMID:
30959123
9.

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial.

Bruner DW, Pugh SL, Lee WR, Hall WA, Dignam JJ, Low D, Swanson GP, Shah AB, Malone S, Michalski JM, Dayes IS, Seaward SA, Nguyen PL, Pisansky TM, Chen Y, Sandler HM, Movsas B.

JAMA Oncol. 2019 May 1;5(5):664-670. doi: 10.1001/jamaoncol.2018.6752. Erratum in: JAMA Oncol. 2019 Apr 4;:.

PMID:
30763425
10.

Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.

Dignam JJ, Hamstra DA, Lepor H, Grignon D, Brereton H, Currey A, Rosenthal S, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Sandler HM.

J Clin Oncol. 2019 Jan 20;37(3):213-221. doi: 10.1200/JCO.18.00154. Epub 2018 Dec 7.

PMID:
30526194
11.

Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Roach M, Moughan J, Lawton CAF, Dicker AP, Zeitzer KL, Gore EM, Kwok Y, Seider MJ, Hsu IC, Hartford AC, Horwitz EM, Yamoah K, Jones CU, Michalski JM, Lee WR, Pisansky TM, Rabinovitch R, Rotman M, Pryzant RM, Kim HE, Thomas CR Jr, Shipley WU, Sandler HM.

Lancet Oncol. 2018 Nov;19(11):1504-1515. doi: 10.1016/S1470-2045(18)30528-X. Epub 2018 Oct 10. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

12.

A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526).

Crook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M 3rd, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):335-343. doi: 10.1016/j.ijrobp.2018.09.039. Epub 2018 Oct 9.

PMID:
30312717
13.

Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients.

Routman DM, Funk RK, Stish BJ, Mynderse LA, Wilson TM, McLaren R, Harmsen WS, Mara K, Deufel CL, Furutani KM, Haddock MG, Pisansky TM, Choo CR, Davis BJ.

Brachytherapy. 2019 Jan - Feb;18(1):1-7. doi: 10.1016/j.brachy.2018.09.003. Epub 2018 Oct 4.

PMID:
30293836
14.

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

Bekelman JE, Rumble RB, Chen RC, Pisansky TM, Finelli A, Feifer A, Nguyen PL, Loblaw DA, Tagawa ST, Gillessen S, Morgan TM, Liu G, Vapiwala N, Haluschak JJ, Stephenson A, Touijer K, Kungel T, Freedland SJ.

J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606. [Epub ahead of print]

PMID:
30183466
15.

Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.

Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA.

JAMA Oncol. 2018 May 10;4(5):e175230. doi: 10.1001/jamaoncol.2017.5230. Epub 2018 May 10. Erratum in: JAMA Oncol. 2018 May 1;4(5):751.

16.

Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.

Eur Urol. 2018 Jul;74(1):99-106. doi: 10.1016/j.eururo.2017.10.009. Epub 2017 Nov 9.

PMID:
29128208
17.

GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer.

Robinson JL, Tzou KS, Parker AS, Heckman MG, Wu KJ, Hilton TW, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Buskirk SJ.

Br J Radiol. 2017 Jul;90(1075):20170174. doi: 10.1259/bjr.20170174. Epub 2017 Jun 16.

18.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. doi: 10.1016/j.ijrobp.2017.02.004. Epub 2017 Feb 12.

19.

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG.

N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529.

20.

Reply to T. Seisen et al and P. Ghadjar et al.

Tendulkar RD, Agrawal S, Pisansky TM.

J Clin Oncol. 2017 May 1;35(13):1491-1492. doi: 10.1200/JCO.2016.70.7992. Epub 2017 Jan 30. No abstract available.

PMID:
28135134
21.

Reply to N. Fossati et al.

Pisansky TM, Stish BJ.

J Clin Oncol. 2017 Feb;35(4):470-471. doi: 10.1200/JCO.2016.70.6119. Epub 2016 Nov 7. No abstract available.

PMID:
28129528
22.

Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):526-535. doi: 10.1016/j.ijrobp.2016.11.014. Epub 2016 Nov 17.

23.

In Reply to Ghadjar et al.

Pisansky TM, Tendulkar RD.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):439-440. doi: 10.1016/j.ijrobp.2016.10.025. No abstract available.

PMID:
28068253
24.

Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases.

Al-Hallaq HA, Chmura SJ, Salama JK, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Robinson CG, Pisansky TM, Winter KA, White JR, Xiao Y, Matuszak MM.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):155-163. doi: 10.1016/j.ijrobp.2016.09.030. Epub 2016 Sep 28.

25.

Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study.

Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1046-1053. doi: 10.1016/j.ijrobp.2016.08.043. Epub 2016 Sep 3.

PMID:
27745980
26.

Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.

Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ.

J Clin Oncol. 2016 Oct 20;34(30):3648-3654. doi: 10.1200/JCO.2016.67.9647.

PMID:
27528718
27.

Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.

Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ.

J Clin Oncol. 2016 Nov 10;34(32):3864-3871. doi: 10.1200/JCO.2016.68.3425.

PMID:
27480153
28.

Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases.

Al-Hallaq HA, Chmura S, Salama JK, Winter KA, Robinson CG, Pisansky TM, Borges V, Lowenstein JR, McNulty S, Galvin JM, Followill DS, Timmerman RD, White JR, Xiao Y, Matuszak MM.

Pract Radiat Oncol. 2016 Nov - Dec;6(6):e291-e298. doi: 10.1016/j.prro.2016.05.004. Epub 2016 May 20.

29.

Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D'Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM.

J Clin Oncol. 2016 Jul 10;34(20):2325-32. doi: 10.1200/JCO.2016.67.0448. Epub 2016 Apr 4.

30.

An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer.

Heckman MG, Robinson JL, Tzou KS, Parker AS, Wu KJ, Hilton TW, Howat WJ, Miller JL, Kreinest PA, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Carroll JS, Buskirk SJ.

PLoS One. 2016 Mar 17;11(3):e0151785. doi: 10.1371/journal.pone.0151785. eCollection 2016.

31.

Salvage Radiotherapy for Postoperative Biochemical Failure of Prostate Cancer: The Path Toward Personalized Medicine.

Pisansky TM.

Eur Urol. 2016 Oct;70(4):597-598. doi: 10.1016/j.eururo.2016.01.033. Epub 2016 Jan 29. No abstract available.

PMID:
26831623
32.

Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review.

Mayo CS, Pisansky TM, Petersen IA, Yan ES, Davis BJ, Stafford SL, Garces YI, Miller RC, Martenson JA, Mutter RW, Choo R, Hallemeier CL, Laack NN, Park SS, Ma DJ, Olivier KR, Keole SR, Fatyga M, Foote RL, Haddock MG.

Pract Radiat Oncol. 2016 Jul-Aug;6(4):e117-26. doi: 10.1016/j.prro.2015.11.001. Epub 2016 Jan 26. Review.

PMID:
26825250
33.

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy.

Lee RJ, Tzou KS, Heckman MG, Hobbs CJ, Rawal B, Diehl NN, Peterson JL, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Wong W, Schild S, Pisansky TM, Buskirk SJ.

BJU Int. 2016 Aug;118(2):236-42. doi: 10.1111/bju.13229. Epub 2015 Aug 22.

34.

Reporting of results in DART01/05 GICOR.

Pisansky TM, Suman VJ, Roach M 3rd, Sandler HM.

Lancet Oncol. 2015 Jun;16(6):e258. doi: 10.1016/S1470-2045(15)70243-3. Epub 2015 May 27. No abstract available.

PMID:
26065604
35.

Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.

Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM.

J Clin Oncol. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22.

36.

Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer--reply.

Pisansky TM, Bruner DW, Greenberg RE.

JAMA. 2014 Aug 20;312(7):748-9. doi: 10.1001/jama.2014.7923. No abstract available.

PMID:
25138339
37.

Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial.

Pisansky TM, Pugh SL, Greenberg RE, Pervez N, Reed DR, Rosenthal SA, Mowat RB, Raben A, Buyyounouski MK, Kachnic LA, Bruner DW.

JAMA. 2014 Apr 2;311(13):1300-7. doi: 10.1001/jama.2014.2626.

38.

PSA screening in men newly diagnosed with colorectal cancer: each according to his group's means?

Davis BJ, Pisansky TM, Catalona WJ.

Oncology (Williston Park). 2013 Oct;27(10):1038, 1040. No abstract available.

39.

Late gastrointestinal morbidity in patients with stage I-II testicular seminoma treated with radiotherapy.

Hallemeier CL, Davis BJ, Pisansky TM, Choo R.

Urol Oncol. 2014 May;32(4):496-500. doi: 10.1016/j.urolonc.2013.10.002. Epub 2013 Dec 12.

PMID:
24332645
40.

Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer.

Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daugherty LC, Vallow LA, Pollack A, Buskirk SJ.

J Radiat Oncol. 2013 Sep 1;2(3):309-314.

41.

Evaluation of Serum Calcium as a Predictor of Biochemical Recurrence following Salvage Radiation Therapy for Prostate Cancer.

Peterson JL, Buskirk SJ, Heckman MG, Parker AS, Diehl NN, Tzou KS, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Pisansky TM.

ISRN Oncol. 2013 Mar 31;2013:239241. doi: 10.1155/2013/239241. Print 2013.

42.

Excellent long-term disease control with modern radiotherapy techniques for stage I testicular seminoma--the Mayo Clinic experience.

Hallemeier CL, Choo R, Davis BJ, Leibovich BC, Costello BA, Pisansky TM.

Urol Oncol. 2014 Jan;32(1):24.e1-6. doi: 10.1016/j.urolonc.2012.08.013. Epub 2013 Mar 11.

PMID:
23490907
43.

Multimodality therapy including surgical resection and intraoperative electron radiotherapy for recurrent or advanced primary carcinoma of the urinary bladder or ureter.

Hallemeier CL, Karnes RJ, Pisansky TM, Davis BJ, Gunderson LL, Leibovich BC, Haddock MG, Choo R.

Am J Clin Oncol. 2013 Dec;36(6):596-600. doi: 10.1097/COC.0b013e31825d52f7.

PMID:
22868244
44.

Long-term outcomes of radiotherapy for stage II testicular seminoma--the Mayo Clinic experience.

Hallemeier CL, Pisansky TM, Davis BJ, Choo R.

Urol Oncol. 2013 Nov;31(8):1832-8. doi: 10.1016/j.urolonc.2012.03.010. Epub 2012 Apr 25.

PMID:
22537538
45.

Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer.

Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ.

Prostate. 2012 Dec 1;72(16):1757-66. doi: 10.1002/pros.22528. Epub 2012 Apr 18.

PMID:
22513981
46.

Impact of sildenafil on marital and sexual adjustment in patients and their wives after radiotherapy and short-term androgen suppression for prostate cancer: analysis of RTOG 0215.

Hanisch LJ, Bryan CJ, James JL, Pisansky TM, Corbett TB, Parliament MB, Stewart CE, Hartford AC, Sandler H, Berk LB, Kachnic L, Bruner DW.

Support Care Cancer. 2012 Nov;20(11):2845-50. doi: 10.1007/s00520-012-1409-8. Epub 2012 Feb 22.

PMID:
22354624
47.

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.

Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB.

J Clin Oncol. 2011 Dec 1;29(34):4491-7. doi: 10.1200/JCO.2011.36.7045. Epub 2011 Oct 31.

48.

Dosimetric effect of interfractional needle displacement in prostate high-dose-rate brachytherapy.

Kovalchuk N, Furutani KM, Macdonald OK, Pisansky TM.

Brachytherapy. 2012 Mar-Apr;11(2):111-8. doi: 10.1016/j.brachy.2011.05.006.

PMID:
21684816
49.

Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.

Kachnic LA, Winter K, Wasserman T, Kelsen D, Ginsberg R, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Willett CG, Minsky BD.

Gastrointest Cancer Res. 2011 Mar;4(2):45-52.

50.

Long-term outcomes after maximal surgical resection and intraoperative electron radiotherapy for locoregionally recurrent or locoregionally advanced primary renal cell carcinoma.

Hallemeier CL, Choo R, Davis BJ, Pisansky TM, Gunderson LL, Leibovich BC, Haddock MG.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1938-43. doi: 10.1016/j.ijrobp.2011.02.026. Epub 2011 Apr 20.

PMID:
21514065

Supplemental Content

Loading ...
Support Center